Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Recommendation of “Hold” from Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $4.94.

CARM has been the topic of several analyst reports. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Evercore ISI reaffirmed an “in-line” rating and set a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Finally, Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $10.00 to $1.00 in a report on Thursday, December 12th.

Carisma Therapeutics Stock Performance

Shares of NASDAQ CARM opened at $0.50 on Friday. The company has a 50-day simple moving average of $0.52 and a 200-day simple moving average of $0.83. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The company has a market cap of $20.88 million, a PE ratio of -0.32 and a beta of 1.56. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.77.

Carisma Therapeutics (NASDAQ:CARM) last announced its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. On average, equities analysts anticipate that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Trading of Carisma Therapeutics

Institutional investors have recently modified their holdings of the company. Wexford Capital LP raised its holdings in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics in the 2nd quarter valued at $40,000. Finally, Barclays PLC lifted its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares in the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.